• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一种快速高效的中和抗体筛选系统及其在 SARS-CoV-2 中的应用。

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2.

机构信息

Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.

Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.

出版信息

Front Immunol. 2021 Mar 22;12:653189. doi: 10.3389/fimmu.2021.653189. eCollection 2021.

DOI:10.3389/fimmu.2021.653189
PMID:33828563
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8019923/
Abstract

After the pandemic of COVID-19, neutralizing antibodies (NAbs) against SARS-CoV-2 have been developed for the prophylactic and therapeutic purposes. However, few methodologies are described in detail on how to rapidly and efficiently generate effective NAbs to SARS-CoV-2. Here, we integrated and optimized a strategically screening method for NAbs, which has enabled us to obtain SARS-CoV-2 receptor-binding domain (RBD) specific NAbs within 6 days, followed by additional 9 days for antibody production and function analysis. Using this method, we obtained 198 specific Abs against SARS-CoV-2 RBD from the blood samples of COVID-19 convalescent patients, and 96 of them showed neutralizing activity. At least 20% of these NAbs exhibited advanced neutralizing potency and high affinity, with the top two NAbs showing half-maximal inhibitory concentration (IC) to block authentic SARS-CoV-2 at 9.88 and 11.13 ng/ml, respectively. Altogether, our study provides an effective methodology with high applicable value for discovering potential preventative and therapeutic NAbs for the emerging infectious diseases.

摘要

在 COVID-19 大流行之后，已经开发出针对 SARS-CoV-2 的中和抗体 (NAb) 用于预防和治疗目的。然而，很少有详细描述如何快速有效地产生针对 SARS-CoV-2 的有效 NAb 的方法。在这里，我们整合并优化了一种针对 NAb 的策略性筛选方法，使我们能够在 6 天内获得 SARS-CoV-2 受体结合域 (RBD) 特异性 NAb，然后再用 9 天进行抗体生产和功能分析。使用这种方法，我们从 COVID-19 康复患者的血液样本中获得了 198 种针对 SARS-CoV-2 RBD 的特异性 Abs，其中 96 种具有中和活性。这些 NAb 中至少有 20% 表现出先进的中和效力和高亲和力，其中前两种 NAb 阻断真实 SARS-CoV-2 的半数最大抑制浓度 (IC) 分别为 9.88 和 11.13ng/ml。总之，我们的研究为发现针对新发传染病的潜在预防和治疗性 NAb 提供了一种有效且具有高应用价值的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b1/8019923/d28f1f870f41/fimmu-12-653189-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b1/8019923/b680b4845413/fimmu-12-653189-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b1/8019923/e925824c0a92/fimmu-12-653189-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b1/8019923/d4a22742f919/fimmu-12-653189-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b1/8019923/8b3a6ddc961b/fimmu-12-653189-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b1/8019923/d28f1f870f41/fimmu-12-653189-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b1/8019923/b680b4845413/fimmu-12-653189-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b1/8019923/e925824c0a92/fimmu-12-653189-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b1/8019923/d4a22742f919/fimmu-12-653189-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b1/8019923/8b3a6ddc961b/fimmu-12-653189-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b1/8019923/d28f1f870f41/fimmu-12-653189-g005.jpg

相似文献

1
A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2.一种快速高效的中和抗体筛选系统及其在 SARS-CoV-2 中的应用。
Front Immunol. 2021 Mar 22;12:653189. doi: 10.3389/fimmu.2021.653189. eCollection 2021.
2
Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.新型单克隆抗体和针对变异 SARS-CoV-2 的重组抗体
Front Immunol. 2021 Aug 30;12:715464. doi: 10.3389/fimmu.2021.715464. eCollection 2021.
3
A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain.针对 SARS-CoV-2 受体结合域的中和抗体的结构景观。
Front Immunol. 2021 Apr 28;12:647934. doi: 10.3389/fimmu.2021.647934. eCollection 2021.
4
Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study.新冠病毒肺炎患者对严重急性呼吸综合征冠状病毒2中和抗体反应的动态变化：一项观察性研究
Signal Transduct Target Ther. 2021 May 18;6(1):197. doi: 10.1038/s41392-021-00611-6.
5
Low Innate Immunity and Lagged Adaptive Immune Response in the Re-Tested Viral RNA Positivity of a COVID-19 Patient.COVID-19 患者再次检测到病毒 RNA 阳性时存在低固有免疫和滞后适应性免疫反应。
Front Immunol. 2021 Jul 1;12:664619. doi: 10.3389/fimmu.2021.664619. eCollection 2021.
6
Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay.SARS-CoV-2 中和抗体与自动化化学发光血清免疫分析的相关性。
J Appl Lab Med. 2021 Mar 1;6(2):491-495. doi: 10.1093/jalm/jfaa195.
7
Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.新冠肺炎患者血清中数月来持续存在对 SARS-CoV-2 的中和活性。
Viruses. 2020 Nov 27;12(12):1357. doi: 10.3390/v12121357.
8
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.COVID-19 恢复期个体中中和抗体的时间成熟提高了对流行的 SARS-CoV-2 变体的效力和广度。
Immunity. 2021 Aug 10;54(8):1841-1852.e4. doi: 10.1016/j.immuni.2021.06.015. Epub 2021 Jul 2.
9
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.针对 SARS-CoV-2 刺突蛋白多个表位的强效中和抗体。
Nature. 2020 Aug;584(7821):450-456. doi: 10.1038/s41586-020-2571-7. Epub 2020 Jul 22.
10
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.针对 SARS-CoV-2 感染的强大中和抗体可长期存在。
Science. 2020 Dec 4;370(6521):1227-1230. doi: 10.1126/science.abd7728. Epub 2020 Oct 28.

引用本文的文献

1
Naive and Memory B Cell BCR Repertoires in Individuals Immunized with an Inactivated SARS-CoV-2 Vaccine.接种灭活新冠病毒疫苗个体中的初始B细胞和记忆B细胞BCR库
Vaccines (Basel). 2025 Apr 8;13(4):393. doi: 10.3390/vaccines13040393.
2
FB5P-seq-mAbs: monoclonal antibody production from FB5P-seq libraries for integrative single-cell analysis of B cells.FB5P-seq单克隆抗体：从FB5P-seq文库生产单克隆抗体用于B细胞的整合单细胞分析。
Front Immunol. 2024 Dec 17;15:1505971. doi: 10.3389/fimmu.2024.1505971. eCollection 2024.
3
Prophylactic efficacy of an intranasal spray with 2 synergetic antibodies neutralizing Omicron.

本文引用的文献

1
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.针对 SARS-CoV-2 刺突蛋白多个表位的强效中和抗体。
Nature. 2020 Aug;584(7821):450-456. doi: 10.1038/s41586-020-2571-7. Epub 2020 Jul 22.
2
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.从 COVID-19 患者中分离出具有强大接近种系 SARS-CoV-2 中和抗体的纵向研究。
Cell. 2020 Aug 20;182(4):843-854.e12. doi: 10.1016/j.cell.2020.06.044. Epub 2020 Jul 13.
3
Potently neutralizing and protective human antibodies against SARS-CoV-2.
针对奥密克戎的 2 种协同中和抗体鼻喷预防效果。
JCI Insight. 2024 Apr 8;9(7):e171034. doi: 10.1172/jci.insight.171034.
4
Real-world effectiveness of an intranasal spray A8G6 antibody cocktail in the post-exposure prophylaxis of COVID-19.鼻内喷雾 A8G6 抗体鸡尾酒在 COVID-19 暴露后预防中的真实世界效果。
Signal Transduct Target Ther. 2023 Oct 23;8(1):403. doi: 10.1038/s41392-023-01656-5.
5
A fine-tuned yeast surface-display/secretion platform enables the rapid discovery of neutralizing antibodies against Clostridioides difficile toxins.经过优化的酵母表面展示/分泌平台可快速发现针对艰难梭菌毒素的中和抗体。
Microb Cell Fact. 2023 Sep 25;22(1):194. doi: 10.1186/s12934-023-02200-4.
6
Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium.二价刺突结合提供针对奥密克戎新兴谱系的持久性：全球联盟的研究结果。
Cell Rep. 2023 Jan 31;42(1):112014. doi: 10.1016/j.celrep.2023.112014. Epub 2023 Jan 12.
7
Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection.来自罕见康复供体的中和抗体引发了新冠病毒变异株感染的抗体依赖性增强。
Front Med (Lausanne). 2022 Oct 19;9:952697. doi: 10.3389/fmed.2022.952697. eCollection 2022.
8
Novel skewed usage of B-cell receptors in COVID-19 patients with various clinical presentations.新型冠状病毒肺炎患者临床表现各异，B 细胞受体出现偏倚性使用。
Immunol Lett. 2022 Sep;249:23-32. doi: 10.1016/j.imlet.2022.08.006. Epub 2022 Aug 31.
9
A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies.一种新型高通量单细胞克隆平台，用于分离和鉴定高亲和力和强效的 SARS-CoV-2 中和抗体。
Antiviral Res. 2022 Jul;203:105349. doi: 10.1016/j.antiviral.2022.105349. Epub 2022 May 28.
10
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.用于新冠治疗和新冠病毒检测的单克隆抗体。
J Biomed Sci. 2022 Jan 4;29(1):1. doi: 10.1186/s12929-021-00784-w.
强效中和和保护 SARS-CoV-2 的人源抗体。
Nature. 2020 Aug;584(7821):443-449. doi: 10.1038/s41586-020-2548-6. Epub 2020 Jul 15.
4
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.快速分离和分析针对 SARS-CoV-2 刺突蛋白的多样化人源单克隆抗体。
Nat Med. 2020 Sep;26(9):1422-1427. doi: 10.1038/s41591-020-0998-x. Epub 2020 Jul 10.
5
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.一种中和性人源抗体结合到了 SARS-CoV-2 的刺突蛋白的 N 端结构域。
Science. 2020 Aug 7;369(6504):650-655. doi: 10.1126/science.abc6952. Epub 2020 Jun 22.
6
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.针对严重急性呼吸系统综合征冠状病毒 2 刺突蛋白的抗体鸡尾酒可预防个体抗体出现的快速突变逃逸。
Science. 2020 Aug 21;369(6506):1014-1018. doi: 10.1126/science.abd0831. Epub 2020 Jun 15.
7
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.来自 COVID-19 患者的强效中和抗体定义了多个易损目标。
Science. 2020 Aug 7;369(6504):643-650. doi: 10.1126/science.abc5902. Epub 2020 Jun 15.
8
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.在人源化小鼠和恢复期患者中的研究产生了一种 SARS-CoV-2 抗体鸡尾酒。
Science. 2020 Aug 21;369(6506):1010-1014. doi: 10.1126/science.abd0827. Epub 2020 Jun 15.
9
Human neutralizing antibodies elicited by SARS-CoV-2 infection.SARS-CoV-2 感染诱导的人体中和抗体。
Nature. 2020 Aug;584(7819):115-119. doi: 10.1038/s41586-020-2380-z. Epub 2020 May 26.
10
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.一种人源中和抗体靶向 SARS-CoV-2 的受体结合位点。
Nature. 2020 Aug;584(7819):120-124. doi: 10.1038/s41586-020-2381-y. Epub 2020 May 26.